公开(公告)号：US20070088075A1

公开(公告)日：2007-04-19

申请号：US11581225

申请日：2006-10-13

申请人： Doug Chou ,  Bertrand Plouvier ,  Peter Pang ,  James Yee ,  Jeffery Wheeler ,  Aregahegn Yifru ,  Allen Davidoff

发明人： Doug Chou ,  Bertrand Plouvier ,  Peter Pang ,  James Yee ,  Jeffery Wheeler ,  Aregahegn Yifru ,  Allen Davidoff

IPC分类号： A61K31/4015

CPC分类号： C07D207/12

摘要： This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same.

摘要翻译： 本发明涉及氘代氨基环己基醚化合物及其制备方法及其使用方法。

公开(公告)号：US20080021005A1

公开(公告)日：2008-01-24

申请号：US11547419

申请日：2005-03-31

申请人： Elizabeth Cheu ,  Lewis Choi ,  Doug Chou ,  Allen Davidoff ,  Alan Ezrin ,  Grace Jung ,  Bertrand Plouvier ,  Aregahegn Yifru

发明人： Elizabeth Cheu ,  Lewis Choi ,  Doug Chou ,  Allen Davidoff ,  Alan Ezrin ,  Grace Jung ,  Bertrand Plouvier ,  Aregahegn Yifru

IPC分类号： C07D207/12 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/497 ,  C07D277/20 ,  C07D401/02 ,  C07D487/02 ,  C07D487/00 ,  C07D403/14 ,  C07D403/02 ,  C07D401/04 ,  C07D281/00 ,  C07D209/82 ,  A61K31/501 ,  A61K31/519 ,  A61K31/55 ,  A61K31/58 ,  A61P9/00

CPC分类号： C07H15/203 ,  A61K47/54 ,  A61K47/555 ,  A61K47/60 ,  A61K51/04 ,  C07B2200/05 ,  C07C257/06 ,  C07D207/12 ,  C07D209/88 ,  C07D209/94 ,  C07F9/572

摘要： This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also disclosed

摘要翻译： 本发明涉及某些离子通道调节化合物的PEG衍生物，药物偶联物和同位素衍生物。 还公开了药物组合物和使用方法

公开(公告)号：US08333974B2

公开(公告)日：2012-12-18

申请号：US12293408

申请日：2007-03-16

申请人： Samuel Weiss ,  Christopher Gregg ,  Allen Davidoff ,  Joseph Tucker

发明人： Samuel Weiss ,  Christopher Gregg ,  Allen Davidoff ,  Joseph Tucker

IPC分类号： A61K38/18 ,  C07K14/59 ,  A61P25/00

CPC分类号： A61K38/1816 ,  A61K38/24

摘要： The present invention provides effective dosing regimes for neural stem cell proliferating agents, kits containing effective dosing regimes for neural stem cell proliferating agents, and uses thereof. In particular, neural stem cell proliferating agents, such as hCG, prolactin and EPO are delivered to mammalian subjects at low doses in a continuous fashion over several days, as opposed to delivery of high doses in a short period of time.

摘要翻译： 本发明提供神经干细胞增殖剂的有效给药方案，含有神经干细胞增殖剂的有效给药方案的试剂盒及其用途。 特别地，神经干细胞增殖剂，例如hCG，催乳素和EPO在几天内以连续的方式以低剂量递送到哺乳动物受试者，而不是在短时间内递送高剂量。

公开(公告)号：US20120270779A1

公开(公告)日：2012-10-25

申请号：US13401323

申请日：2012-02-21

申请人： Samuel Weiss ,  Christopher Gregg ,  Allen Davidoff ,  Joseph E. Tucker

发明人： Samuel Weiss ,  Christopher Gregg ,  Allen Davidoff ,  Joseph E. Tucker

IPC分类号： A61K38/24 ,  A61P25/28 ,  A61P25/00 ,  A61K38/22

CPC分类号： A61K38/1816 ,  A61K38/24

摘要： Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions and methods can be used continuously or intermittently in various dosing regimens.

摘要翻译： 本文提供了神经干细胞增殖和分化剂的有效给药方案，包含神经干细胞增殖和分化剂的有效给药方案的试剂盒及其用途。 这些试剂盒和方法可以被急性或长期地用于治疗神经变性疾病或病症。 此外，组合物和方法可以以各种给药方案连续或间歇使用。

公开(公告)号：US20080039389A1

公开(公告)日：2008-02-14

申请号：US11687302

申请日：2007-03-16

申请人： Samuel Weiss ,  Christopher Gregg ,  Allen Davidoff ,  Joseph E. Tucker

发明人： Samuel Weiss ,  Christopher Gregg ,  Allen Davidoff ,  Joseph E. Tucker

IPC分类号： A61K38/18 ,  A61K38/09 ,  A61M31/00

CPC分类号： A61K38/1816 ,  A61K38/24

摘要： Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions and methods can be used continuously or intermittently in various dosing regimens.

摘要翻译： 本文提供了神经干细胞增殖和分化剂的有效给药方案，包含神经干细胞增殖和分化剂的有效给药方案的试剂盒及其用途。 这些试剂盒和方法可以被急性或长期地用于治疗神经变性疾病或病症。 此外，组合物和方法可以以各种给药方案连续或间歇使用。

公开(公告)号：US20090081205A1

公开(公告)日：2009-03-26

申请号：US12293408

申请日：2007-03-16

申请人： Samuel Weiss ,  Christopher Gregg ,  Allen Davidoff ,  Joseph Tucker

发明人： Samuel Weiss ,  Christopher Gregg ,  Allen Davidoff ,  Joseph Tucker

IPC分类号： A61K39/395

CPC分类号： A61K38/1816 ,  A61K38/24

摘要： The present invention provides effective dosing regimes for neural stem cell proliferating agents, kits containing effective dosing regimes for neural stem cell proliferating agents, and uses thereof. In particular, neural stem cell proliferating agents, such as hCG, prolactin and EPO are delivered to mammalian subjects at low doses in a continuous fashion over several days, as opposed to delivery of high doses in a short period of time.

摘要翻译： 本发明提供神经干细胞增殖剂的有效给药方案，含有神经干细胞增殖剂的有效给药方案的试剂盒及其用途。 特别地，神经干细胞增殖剂，例如hCG，催乳素和EPO在几天内以连续的方式以低剂量递送到哺乳动物受试者，而不是在短时间内递送高剂量。

公开(公告)号：US20230134136A1

公开(公告)日：2023-05-04

申请号：US17911789

申请日：2021-03-15

申请人： Allen DAVIDOFF

发明人： Allen Davidoff

IPC分类号： A61K38/44 ,  A61K45/06 ,  A61P13/12 ,  A61P31/14 ,  C12N9/06

摘要： This invention relates to formulations of uric acid lowering agent(s) (UALA) designed to inhibit xanthine oxidase and/or decrease serum or tissue uric acid concentration for the treatment and prevention of morbidities and mortality during viral infection. For example, acute kidney injury due to coronavirus infection by administering a therapeutically effective amount of an agent capable of inhibiting xanthine oxidase and/or decreasing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating and preventing acute kidney injury and health consequences due to coronavirus infection.

公开(公告)号：US11406713B2

公开(公告)日：2022-08-09

申请号：US14776905

申请日：2014-03-17

申请人： Allen Davidoff

发明人： Allen Davidoff

IPC分类号： A61K31/519 ,  A61K47/18 ,  A61K9/14 ,  A61K9/19 ,  A61K9/00 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/714 ,  A61K31/455 ,  A61K31/525 ,  A61K31/51 ,  A61K31/593 ,  A61K31/197 ,  A61K31/198 ,  A61J1/00

摘要： Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions can be used to treat a disease or medical condition that involves elevated uric acid levels.